Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMerck Statement on HIV Vaccine Trial
Merck & Co., 09/25/09
Merck offered the following statement after the announcement of results from the Phase III HIV vaccine trial. "The development of a vaccine to prevent HIV infection represents the best hope for containing the AIDS pandemic. This scientific pursuit has been one of the most challenging tasks facing modern medicine. The data released from the RV 144 study are an important contribution to the growing body of scientific knowledge in HIV vaccine research," said Dr. Peter S. Kim, Ph.D., president, Merck Research Laboratories.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Sponsor
Article Search
Sponsor